Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19
Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered into a sponsored research agreement
Read moreRevive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered into a sponsored research agreement
Read moreRevive Therapeutics (CSE: RVV) has filed for orphan drug designation with the US Food and Drug Administration. The filing relates
Read moreRevive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an oral thin film delivery system
Read moreRevive Therapeutics (CSE: RVV) this morning revealed that it has received positive results for a pre-clinical study that evaluated the
Read moreRevive Therapeutics (CSE: RVV) this morning provided an update on the status of its phase 3 clinical trial for the
Read morePharmaTher (CSE: PHRM) has seen the completion of the sale of its psilocybin program to that of Revive Therapeutics (CSE:
Read moreRevive Therapeutics (CSE: RVV) this morning announced the closing of its bought deal financing. Originally announced at a figure of
Read moreRevive Therapeutics (CSE: RVV) this morning provided an update in connection with its ongoing cannabinoid pharmaceuticals program. More specifically, the
Read moreRevive Therapeutics (CSE: RVV) has upsized the bought deal financing announced last night. Originally pegged at $10.0 million in gross
Read moreRevive Therapeutics (CSE: RVV) this evening announced that it will be conducting a bought deal financing, lead by Leede Jones
Read more